AdaptHealth (AHCO) EBITDA (2018 - 2026)

AdaptHealth has reported EBITDA for 9 years, with the latest figure at $107.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 4.7% year-over-year to $107.1 million; the trailing twelve-month figure through Mar 2026 stood at $447.1 million (down 23.1% YoY), and the FY2025 full-year result was $452.5 million, down 25.44% from the prior year.
• EBITDA for Q1 2026 stood at $107.1 million, up from $19.2 million in the prior quarter.
• The five-year high for EBITDA was $182.7 million in Q4 2024, with the low at -$370.7 million in Q3 2023.
• Average EBITDA over 5 years is $83.5 million, with a median of $128.6 million recorded in 2022.
• Year-over-year, EBITDA slumped 373.91% in 2023 and surged 239.44% in 2024.
• Tracing AHCO's EBITDA over 5 years: stood at $119.0 million in 2022, then slumped by 210.06% to -$131.0 million in 2023, then surged by 239.44% to $182.7 million in 2024, then plunged by 89.48% to $19.2 million in 2025, then jumped by 457.15% to $107.1 million in 2026.
• The last three EBITDA figures came in at $107.1 million (Q1 2026), $19.2 million (Q4 2025), and $154.3 million (Q3 2025), per Business Quant data.

Peer Comparison